利妥昔单抗治疗抗肾小球基底膜肾炎合并抗中性粒细胞胞质抗体阳性及肺部感染1例并文献复习

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (S1): 17-20.

利妥昔单抗治疗抗肾小球基底膜肾炎合并抗中性粒细胞胞质抗体阳性及肺部感染1例并文献复习

钭张琪¹, 杨华¹, 张彬娥¹, 张旭珍¹, 夏宜东², 金烈¹

¹丽水市中心医院,丽水 323000;
²防城港市中医医院,防城港 538021

收稿日期:2024-06-03 出版日期:2024-06-30 发布日期:2024-07-03
通信作者: 金烈,Email：lsjinlie@163.com

Received:2024-06-03 Online:2024-06-30 Published:2024-07-03

摘要/Abstract

摘要： 抗肾小球基底膜（glomerular basement membrane,GBM）肾炎是一种发病率低但死亡率极高的自身免疫性疾病。当同时合并抗中性粒细胞胞质抗体（antineutrophil cytoplasmic antibody,ANCA）阳性时可同时具备ANCA相关性血管炎（antineutrophil cytoplasmic antibody vasculitis,AAV）和抗GBM肾炎的临床特征,表现为急进性肾炎。现作者总结1例2021年8月5日防城港市中医医院收治的抗GBM肾炎合并ANCA阳性患者,经利妥昔单抗（Rituximab）联合激素、环磷酰胺（Cyclophosphamide,CTX）免疫抑制治疗后出现肺部感染,在肾脏功能未能恢复的基础上,经抗感染治疗肺部病变好转,患者病情稳定,各项指标趋于平稳,对该病的临床诊治有一定借鉴意义。

关键词: 抗肾小球基底膜肾炎, 抗中性粒细胞胞质抗体, ANCA相关性血管炎, 利妥昔单抗, 肺部感染

钭张琪, 杨华, 张彬娥, 张旭珍, 夏宜东, 金烈. 利妥昔单抗治疗抗肾小球基底膜肾炎合并抗中性粒细胞胞质抗体阳性及肺部感染1例并文献复习[J]. 中国防痨杂志, 2024, 46(S1): 17-20.

参考文献

[1] Ponticelli C,Calatroni M,Moroni G.Anti-glomerular basement membrane vasculitis. Autoimmunity Reviews,2023,22(1):103-212.
[2] Philip R,Dumont A,Martin Silva N,et al.ANCA and anti-glomerular basement membrane double-positive patients:A systematic review of the literature. Autoimmunity Reviews,2021,20(9):102885.
[3] 王春莹,张婷,许颖. 抗中性粒细胞胞浆抗体的临床疾病分布及特征分析. 成都医学院学报,2023,18(3):298-303.
[4] Van,Beers,Vanderlocht,et al. Detection of Anti-neutrophil Cytoplasmic Antibodies (ANCA) by Indirect Immunofluorescence. Methods in Molecular Biology,2019,19(1):47-62.
[5] Nozaki Y.New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis. Frontiers in immunology,2021,12:631055.
[6] Li ZY,Ma TT,Chen M,et al.The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China. Kidney Diseases,2016,1(4):216-223.
[7] 陈旻,于峰,张颖,等. 426例抗中性粒细胞胞浆抗体相关性小血管炎患者多系统临床表现和肾脏病理分析. 中华内科杂志,2005,11(44) :828-830.
[8] 陈惠萍,周虹,刘红,等. 10594例肾活检病理资料分析. 肾脏病与透析肾移植杂志,2000,9(6):501-509.
[9] Cui Z,Zhao J,Jia XY,et al.Anti-glomerular basement membrane disease:outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine,2011,90(5):303-311.
[10] 李丽娟,李晓梅,曾彩虹. 114例抗肾小球基底膜抗体阳性结果分析. 检验医学与临床,2018,21(15):3186-3190.
[11] Leinonen A,Netzer KO,Boutaud A,et al.Goodpasture antigen:Expression of the full-length 〈3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. Kidney International,1999,55(3):926-935.
[12] Cui,Zhao,Wang,et al. Antibodies to alpha 5 chain of collagen IV are pathogenic in Goodpasture’s disease. Journal of Autoimmunity,2016,70:1-11.
[13] Mcadoo SP,Tanna A,Hrukova Z,et al.Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival?frequency of relapse,and outcomes compared to single-seropositive patients.Kidney international,2017,3(14):1-10.
[14] Xiang,Hai Y,Liu,et al. Etiology and Outcome of Crescentic Glomerulonephritis From a Single Center in China:A 10-Year Review. American Journal of Kidney Diseases:The official journal of the National Kidney Foundation,2016,67(3):376-83.
[15] Zhao J,Yang R,Cui Z,et al.Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clinical Practice,2007,107(2):c56-c62.
[16] 付平,苟慎菊. 利妥昔单抗在肾脏疾病中的应用. 肾脏病与透析肾移植杂志,2017,26(1):50-51.
[17] Uematsu-uchida M,Ohira T,Tomita S,et al. Rituximab in treatment of anti-GBM antibody glomerulonephritis:A case report and literature review. Medicine,2019,98(44):17801-17806.
[18] Rovin B,Adler S,Barratt J,et al.Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. 2021.